{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:18:34Z","timestamp":1762273114322,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.farma.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T23:40:32Z","timestamp":1682120432000},"page":"T85-T92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] The needs and medication experience of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A systematic review"],"prefix":"10.1016","volume":"47","author":[{"given":"Ana Isabel","family":"Cachafeiro Pin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Villaverde Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Mart\u00edn Clavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Milena","family":"Silva Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2013","series-title":"Gu\u00eda andaluza de leucemia mieloide cr\u00f3nica [Internet]","author":"L\u00f3pez Garrido","key":"10.1016\/j.farma.2023.02.002_bb0005"},{"issue":"6","key":"10.1016\/j.farma.2023.02.002_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.rce.2016.03.001","article-title":"Leucemia mieloide cr\u00f3nica en Espa\u00f1a: sus caracter\u00edsticas de presentaci\u00f3n han cambiado. Secci\u00f3n espa\u00f1ola del registro poblacional EUTOS","volume":"216","author":"Osorio","year":"2016","journal-title":"Rev. Clin Esp (Barc)."},{"issue":"4","key":"10.1016\/j.farma.2023.02.002_bb0015","article-title":"Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagn\u00f3stico, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.farma.2023.02.002_bb0020","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.farma.2023.02.002_bb0025","first-page":"434","article-title":"Adherencia y toxicidad de los inhibidores de la tirosinquinasa en leucemia mieloide cr\u00f3nica","volume":"37","author":"Gonz\u00e1lez Rosa","year":"2013","journal-title":"Farm Hosp."},{"issue":"22","key":"10.1016\/j.farma.2023.02.002_bb0030","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.farma.2023.02.002_bb0035","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.farma.2023.02.002_bb0040","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.3390\/ijerph18084266","article-title":"Medication experience and adherence to oral chemotherapy: a qualitative study of patients' and health professionals' perspectives","volume":"18","author":"Talens","year":"2021","journal-title":"International Journal of Environmental Research and Public Health."},{"year":"2012","series-title":"Pharmaceutical Care Practice. The Patient Centered Approach to Medication Management","author":"Cipolle","key":"10.1016\/j.farma.2023.02.002_bb0045"},{"author":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH)","key":"10.1016\/j.farma.2023.02.002_bb0050"},{"author":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria (SEFH)","key":"10.1016\/j.farma.2023.02.002_bb0055"},{"issue":"5","key":"10.1016\/j.farma.2023.02.002_bb0060","first-page":"34","article-title":"Entrevistas en profundidad: t\u00e9cnica complementaria a las entrevistas cl\u00ednicas en las intervenciones basadas en necesidades del paciente","volume":"23","author":"P\u00e9rez Rodr\u00edguez","year":"2021","journal-title":"Pharm Care Esp."},{"issue":"6","key":"10.1016\/j.farma.2023.02.002_bb0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/COC.0000000000000818","article-title":"Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review","volume":"44","author":"Heiney","year":"2021","journal-title":"Am J Clin Oncol."},{"key":"10.1016\/j.farma.2023.02.002_bb0070","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/PPA.S269355","article-title":"Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review","volume":"15","author":"Tan","year":"2021","journal-title":"Patient Preference and Adherence."},{"issue":"3","key":"10.1016\/j.farma.2023.02.002_bb0075","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.farma.2023.02.002_bb0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1467-9566.t01-1-00337","article-title":"The illness experience: state of knowledge and perspectives for research","volume":"25","author":"Pierret","year":"2003","journal-title":"Sociol Health Illn."},{"issue":"1","key":"10.1016\/j.farma.2023.02.002_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/pharmacy9010007","article-title":"The medication experience: a concept analysis","volume":"9","author":"Hillman","year":"2020","journal-title":"Pharmacy (Basel)."},{"key":"10.1016\/j.farma.2023.02.002_bb0090","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"issue":"10","key":"10.1016\/j.farma.2023.02.002_bb0095","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/1049732312452938","article-title":"Beyond PICO: The SPIDER tool for qualitative evidence synthesis","volume":"22","author":"Cooke","year":"2012","journal-title":"Qualitative Health Research."},{"issue":"9","key":"10.1016\/j.farma.2023.02.002_bb0100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: a synthesis of recommendations","volume":"89","author":"O'Brien","year":"2014","journal-title":"Acad Med."},{"key":"10.1016\/j.farma.2023.02.002_bb0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ejh.13155","article-title":"Needs for information and reasons for (non) adherence in chronic myeloid leukemia: Be aware of social activities disturbing daily routines","volume":"101","author":"Boons","year":"2018","journal-title":"Eur J Haematol."},{"issue":"1","key":"10.1016\/j.farma.2023.02.002_bb0110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11096-013-9867-8","article-title":"Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukemia outpatients","volume":"36","author":"Chen","year":"2014","journal-title":"Int J Clin Pharm."},{"issue":"10","key":"10.1016\/j.farma.2023.02.002_bb0115","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1590\/0102-311X00171613","article-title":"Antes e depois da CML: experi\u00eancias e dimens\u00f5es da leucemia mieloide cr\u00f4nica como uma rotura biogr\u00e1fica","volume":"30","author":"Alzate","year":"2014","journal-title":"Cadernos de Sa\u00fade P\u00fablica."},{"issue":"2","key":"10.1016\/j.farma.2023.02.002_bb0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S1478951513001260","article-title":"Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study","volume":"13","author":"Wu","year":"2015","journal-title":"Palliat Support Care."},{"issue":"2","key":"10.1016\/j.farma.2023.02.002_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40271-013-0006-3","article-title":"The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach","volume":"6","author":"Guilhot","year":"2013","journal-title":"Patient."},{"key":"10.1016\/j.farma.2023.02.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2020.101730","article-title":"Experiences of living with chronic myeloid leukemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies","volume":"45","author":"Hewison","year":"2020","journal-title":"Eur J Oncol Nurs."},{"issue":"10","key":"10.1016\/j.farma.2023.02.002_bb0135","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11136-017-1611-8","article-title":"Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine","volume":"26","author":"Graffigna","year":"2017","journal-title":"Qual Life Res."},{"key":"10.1016\/j.farma.2023.02.002_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7525-11-167","article-title":"Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective","volume":"11","author":"Hirji","year":"2013","journal-title":"Health Qual Life Outcomes."},{"key":"10.1016\/j.farma.2023.02.002_bb0145","first-page":"71","article-title":"La fuerza cultural de la experiencia con la medicaci\u00f3n. Una reflexi\u00f3n autoetnogr\u00e1fica desde la perplejidad","volume":"9","author":"Silva-Castro","year":"2021","journal-title":"Revista (Con)textos"},{"issue":"4","key":"10.1016\/j.farma.2023.02.002_bb0150","first-page":"19","article-title":"Incorporaci\u00f3n del Counseling a la Gesti\u00f3n Integral de la Medicaci\u00f3n para gestionar emociones que afectan enfermedades cr\u00f3nicas","volume":"23","author":"Barrera Salvador","year":"2021","journal-title":"Pharm Care Esp."},{"year":"1979","series-title":"Compliance in health care","author":"Haynes","key":"10.1016\/j.farma.2023.02.002_bb0155"},{"issue":"4","key":"10.1016\/j.farma.2023.02.002_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjms.2016.01.010","article-title":"Medication adherence: truth and consequences","volume":"351","author":"Brown","year":"2016","journal-title":"Am J Med Sci."},{"issue":"5","key":"10.1016\/j.farma.2023.02.002_bb0165","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/her\/cyu023","article-title":"A matter of trust: patient barriers to primary medication adherence","volume":"29","author":"Polinski","year":"2014","journal-title":"Health Educ Res."},{"issue":"2","key":"10.1016\/j.farma.2023.02.002_bb0170","first-page":"63","article-title":"Gesti\u00f3n integral de la farmacoterapia en la atenci\u00f3n del paciente oncol\u00f3gico","volume":"23","author":"Silva-Castro","year":"2013","journal-title":"Rev. O.F.I.L."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:05Z","timestamp":1761106625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634323000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1130634323000156"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2023.02.002","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] The needs and medication experience of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2022.11.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}